Guideline | Country | Year | Symptom management | Antivirals | Antibiotics | Prophylaxis |
China (MoH)54 | China | 2003 | R | NS | R* | R |
Dermatology Advisor47 | Global | 2017 | NS | C | NS | R |
DermNet48 | Global | 2014 | NS | C | NS | R |
ECDC56 | Europe | 2019 | NS | NS | NS | R |
eMedicine49 | Global | 2020 | NS | C | NS | R |
Ireland HPSC53 | Ireland | 2021 | NS | C | NS | R |
Medscape51 | Global | 2019 | R | NS | NS | R |
NCDC44 | Nigeria | 2019 | R | NS | R* | R |
PHE/UKHSA52 | England | 2019 | NS | C | NS | R |
Singapore FETP46 | Singapore | 2020 | NS | NS | NS | R |
Taiwan CDC45 | Taiwan | 2009 | NS | NS | NS | R |
UpToDate50 | Global | 2021 | R | C | NS | R |
US CDC55 | USA | 2018 | NS | C | NS | R |
WHO18 | Global | 2019 | NS | C | NS | R |
*If secondary complications; C, considered; NS, not specified; R, recommended.
CDC, Centers for Disease Control; ECDC, European Centre for Disease Control and Prevention; FETP, Singapore Field Epidemiology Training Programme; HPSC, Health Protection Surveillance Centre; MoH, Ministry of Health; NCDC, Nigeria Centre for Disease Control; PHE, Public Health England; UKHSA, UK Health Security Agency.